|Bid||28.05 x 100|
|Ask||35.65 x 100|
|Day's Range||33.65 - 34.65|
|52 Week Range||23.30 - 39.20|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 1, 2018 - May 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||45.00|
MALVERN, Pa., April 19, 2018-- BioTelemetry, Inc. will release its first quarter 2018 earnings on Wednesday, April 25 at 4:00 PM Eastern Time.. The BioTelemetry quarterly conference call will be held at ...
What: BioTelemetry, Inc. will visit the Nasdaq MarketSite in Times Square in celebration of its 10th listing anniversary. BioTelemetry, Inc. is the leading wireless medical technology company focused on ...
Amedisys (AMED) is a healthcare services company with a focus on providing home care through three segments: home health, hospice, and personal care. Of the 11 analysts covering Amedisys in March 2018, three analysts have given the stock a “strong buy” rating. Two analysts have given the stock a “buy” rating, while six analysts have given it a “hold” rating.
BioTelemetry’s (BEAT) business strategy is to solidify its position as a leading provider of outpatient cardiac monitoring services, expand in the research market, and leverage its monitoring platform in new markets. In order to increase the demand for its portfolio of outpatient cardiac monitoring solutions, BioTelemetry is focusing on educating cardiologists, electrophysiologists, and neurologists on the benefits of using mobile cardiac telemetry for arrhythmia monitoring while stressing the increased diagnostic yield and ability to deliver more effective treatments.
BioTelemetry (BEAT) provides monitoring services and digital population health management for healthcare providers, medical device manufacturing, and centralized core laboratory services for clinical research. In July 2017, BioTelemetry acquired LifeWatch, a supplier of mobile cardiac monitoring solutions. The acquisition is expected to help BioTelemetry create a comprehensive connected healthcare platform and deliver solutions in the market more effectively.
BioTelemetry (BEAT) operates in three segments: healthcare, research, and technology. The healthcare segment contributed 81% of BioTelemetry’s total revenues in fiscal 2017. Under this segment, BioTelemetry offers a full spectrum of solutions with a single source of cardiac monitoring services to cardiologists, electrophysiologists, neurologists, and primary care physicians.
NEW YORK, March 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Stock Monitor: BioTelemetry Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 1, 2018 / Active-Investors.com has just released a free earnings report on Laboratory Corp. of America Holdings (NYSE: ...
Stock Monitor: BioTelemetry Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 28, 2018 / Active-Investors.com has just released a free research report on PerkinElmer, Inc. (NYSE: PKI ). If you ...
BioTelemetry Inc (NASDAQ:BEAT) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
The Malvern, Pennsylvania-based company said it had a loss of 48 cents per share. Earnings, adjusted for non-recurring costs, came to 32 cents per share. The results exceeded Wall Street expectations. ...
Company Delivers Record Revenue and Adjusted EBITDA Exceeds Expectations. MALVERN, Pa., Feb. 22, 2018-- BioTelemetry, Inc., the leading mobile and wireless medical technology company focused on the delivery ...
On Thursday, BioTelemetry (NASDAQ: BEAT ) will release its latest earnings report. Here is Benzinga's outlook for the company. Earnings and Revenue Based on BioTelemetry management projections, analysts ...
MALVERN, Pa., Feb. 12, 2018-- BioTelemetry, Inc. will release its fourth quarter 2017 earnings on Thursday, February 22 nd at 4:00 PM Eastern Time.. The BioTelemetry quarterly conference call will be held ...
Government bodies like Medicare, Medicaid and the U.S. FDA are signaling that remote patient monitoring is going to be a huge industry over the coming decade; agencies improving the environment for medical ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to BioTelemetry, Inc. Here are 5 ETFs with the largest exposure to BEAT-US. Comparing the performance and risk of BioTelemetry, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis BioTelemetry, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of BioTelemetry, Inc. – iRadimed Corp, Neovasc Inc. and InfuSystem Holdings, Inc. (IRMD-US, NVCN-US and INFU-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 81.02 ... Read more (Read more...)
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives BioTelemetry, Inc. a score of 72. Our analysis is based on comparing BioTelemetry, Inc. with the following peers – NuVasive, Inc., iRadimed Corp, Neovasc Inc. and InfuSystem Holdings, Inc. (NUVA-US, IRMD-US, NVCN-US and INFU-US). Investment Outlook BioTelemetry, Inc. has a fundamental score of 72 and has a ... Read more (Read more...)